Oberg, D., Yanover, E., Adam, V., Sweeney, K., Costas, C., Lemoine, N. R., & Halldén, G. (2010). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clinical cancer research, 16(2), 541. https://doi.org/10.1158/1078-0432.CCR-09-1960
Citace podle Chicago (17th ed.)Oberg, Daniel, Eva Yanover, Virginie Adam, Katrina Sweeney, Celina Costas, Nick R. Lemoine, a Gunnel Halldén. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research 16, no. 2 (2010): 541. https://doi.org/10.1158/1078-0432.CCR-09-1960.
Citace podle MLA (9th ed.)Oberg, Daniel, et al. "Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers." Clinical Cancer Research, vol. 16, no. 2, 2010, p. 541, https://doi.org/10.1158/1078-0432.CCR-09-1960.